Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SEL1L2 is an adaptor protein that participates in the endoplasmic reticulum-associated degradation (ERAD) pathway by linking the E3 ubiquitin ligase SYVN1 (HRD1) complex to misfolded cargo proteins destined for proteasomal degradation[1][3][5]. It is evolutionarily related to SEL1L and shares structural features, but SEL1L2 is less well characterized, with its specific protein-protein interactions, tissue distribution, and functional importance remaining subjects for future research[1][3][5]. The ERAD pathway regulates ER protein quality, contributing to cellular homeostasis and response to stress; in this machinery, SEL1L2 is thought to help scaffold the degradation process but has not been directly linked to disease pathology or targeted therapies[1][2].
Not applicable; drugs do not directly target SEL1L2. General ERAD modulation occurs through E3 ligase inhibition or proteasome inhibition[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein sel-1 homolog 2 (SEL1L2).